Show simple item record

Blood clearance of radioactively labelled cis-diammine 1,1-cyclobutane dicarboxylate platinum (II) (CBDCA) in cancer patients.

dc.contributor.authorSharma, H
dc.contributor.authorThatcher, Nick
dc.contributor.authorBaer, J
dc.contributor.authorZaki, A
dc.contributor.authorSmith, A
dc.contributor.authorMcAuliffe, C A
dc.contributor.authorCrowther, Derek
dc.contributor.authorOwens, S
dc.contributor.authorFox, Brian W
dc.date.accessioned2010-07-21T12:36:05Z
dc.date.available2010-07-21T12:36:05Z
dc.date.issued1983
dc.identifier.citationBlood clearance of radioactively labelled cis-diammine 1,1-cyclobutane dicarboxylate platinum (II) (CBDCA) in cancer patients. 1983, 11 (1):5-7 Cancer Chemother. Pharmacol.en
dc.identifier.issn0344-5704
dc.identifier.pmid6349844
dc.identifier.doi10.1007/BF00257407
dc.identifier.urihttp://hdl.handle.net/10541/108061
dc.description.abstractThe blood and urinary clearances of cis-diammine 1,1-cyclobutane dicarboxylate platinum(II) (CBDCA, JM8) were determined in four patients with malignancy. A 40 muCi iv injection of 191 Pt/193 Pt (3:1)-labelled CBDCA was followed by serial blood and urine sampling to 72 h. The blood clearance was triphasic, mean values for the fast, intermediate, and slow phases being 10.8 min, 2.5 h, and 125 h, respectively. The fraction of activity excreted in the urine within the first 6 h had a mean value of 66.7%, contrasting with 26.4% for cisplatin. There was only a small fraction of CBDCA excreted by the slow phase (1.5%) as against an average of 20% for CHIP and 27% for cisplatin. The early and rapid renal clearance of CBDCA may account for reduced nephrotoxicity.
dc.language.isoenen
dc.subjectBronchial Canceren
dc.subject.meshAntineoplastic Agents
dc.subject.meshBronchial Neoplasms
dc.subject.meshCarboplatin
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshMale
dc.subject.meshMelanoma
dc.subject.meshMetabolic Clearance Rate
dc.subject.meshMiddle Aged
dc.subject.meshOrganoplatinum Compounds
dc.titleBlood clearance of radioactively labelled cis-diammine 1,1-cyclobutane dicarboxylate platinum (II) (CBDCA) in cancer patients.en
dc.typeArticleen
dc.contributor.departmentDepartment of Medical Biophysics, University of Manchester, Medical School, Manchester.en
dc.identifier.journalCancer Chemotherapy and Pharmacologyen
html.description.abstractThe blood and urinary clearances of cis-diammine 1,1-cyclobutane dicarboxylate platinum(II) (CBDCA, JM8) were determined in four patients with malignancy. A 40 muCi iv injection of 191 Pt/193 Pt (3:1)-labelled CBDCA was followed by serial blood and urine sampling to 72 h. The blood clearance was triphasic, mean values for the fast, intermediate, and slow phases being 10.8 min, 2.5 h, and 125 h, respectively. The fraction of activity excreted in the urine within the first 6 h had a mean value of 66.7%, contrasting with 26.4% for cisplatin. There was only a small fraction of CBDCA excreted by the slow phase (1.5%) as against an average of 20% for CHIP and 27% for cisplatin. The early and rapid renal clearance of CBDCA may account for reduced nephrotoxicity.


This item appears in the following Collection(s)

Show simple item record